The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of low neutrophil-to-lymphocyte ratios (NLR) and high lymphocyte-to-monocyte ratios (LMR) with overall survival and response to induction chemotherapy (IC) when used to select patients (pts) with locally advanced squamous cell of the larynx (LSCC) for combined chemoradiation (CRT).
 
Zachary Risch
Stock and Other Ownership Interests - Alnylam; Asterias Biotherapeutics; Geron; Oncolytics; Pfizer; Sangamo Bioscience
 
Emily Bellile
No Relationships to Disclose
 
Ryan Townsend
No Relationships to Disclose
 
Paul Swiecicki
Research Funding - Ascentage Pharma Group; Pfizer
 
Keith Casper
No Relationships to Disclose
 
Kelly M Malloy
No Relationships to Disclose
 
Norman D Hogikyan
No Relationships to Disclose
 
Matthew E Spector
No Relationships to Disclose
 
Andrew Shuman
No Relationships to Disclose
 
Chaz Stucken
No Relationships to Disclose
 
Steven Bennett Chinn
No Relationships to Disclose
 
Douglas Brian Chepeha
No Relationships to Disclose
 
Shruti Jolly
Honoraria - Varian Medical Systems
Consulting or Advisory Role - AstraZeneca; Varian Medical Systems
 
Michelle Lynn Mierzwa
No Relationships to Disclose
 
Carol Rossier Bradford
No Relationships to Disclose
 
Avraham Eisbruch
No Relationships to Disclose
 
Thomas E. Carey
No Relationships to Disclose
 
Mark E Prince
No Relationships to Disclose
 
Gregory T. Wolf
No Relationships to Disclose
 
Francis P. Worden
Consulting or Advisory Role - Bristol-Myers Squibb; Loxo; Merck
Research Funding - Bristol-Myers Squibb; Eisai (Inst); Loxo; Merck (Inst); Pfizer (Inst); Progenics